Bruce Booth Sells 115,856 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 115,856 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $30.61, for a total value of $3,546,352.16. Following the completion of the transaction, the director directly owned 751,664 shares of the company’s stock, valued at $23,008,435.04. The trade was a 13.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total value of $1,989,099.45.

Sionna Therapeutics Stock Performance

NASDAQ SION opened at $32.72 on Friday. The stock’s 50-day simple moving average is $25.23 and its two-hundred day simple moving average is $18.36. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $34.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.27.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Sionna Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Jones Trading initiated coverage on Sionna Therapeutics in a report on Monday, September 8th. They issued a “buy” rating and a $46.00 price objective on the stock. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 price objective on the stock. Finally, Raymond James Financial initiated coverage on Sionna Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Institutional Trading of Sionna Therapeutics

Large investors have recently modified their holdings of the business. Siren L.L.C. bought a new stake in shares of Sionna Therapeutics in the first quarter worth about $3,400,000. Zimmer Partners LP bought a new stake in shares of Sionna Therapeutics in the first quarter worth about $2,484,000. Goldman Sachs Group Inc. bought a new stake in shares of Sionna Therapeutics in the first quarter worth about $667,000. Alyeska Investment Group L.P. bought a new stake in Sionna Therapeutics during the 1st quarter valued at approximately $1,948,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Sionna Therapeutics during the 1st quarter valued at approximately $676,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.